Lenalidomide (CC-5013)

For research use only.

Catalog No.S1029

117 publications

Lenalidomide (CC-5013) Chemical Structure

CAS No. 191732-72-6

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.

Selleck's Lenalidomide (CC-5013) has been cited by 117 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
Targets
CRBN [3]
()
VEGF [1]
()
TNF-α [1]
(PBMCs)
13 nM
In vitro

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwMUWwN|gh|ryP MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
L-363 NXHtRms5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPweotxUUN3ME2yMlkzOjF{IN88US=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
JAR MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfTNZRZUUN3ME2yMlk4ODBzIN88US=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
EoL-1-cell MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:0TWM2OD12LkGwOVE2KM7:TR?= NXXZRnVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
BT-549 M1HkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZwMkG4OFkh|ryP NWjvUZZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
SK-NEP-1 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVntXoxyUUN3ME23Mlg6PTF{IN88US=> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
BV-173 NEGyWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrnTmF2UUN3ME24MlY4PTh3IN88US=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HMV-II MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzhfGJLUUN3ME2xNE4xOTd{IN88US=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HCC1806 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XEVWlEPTB;MUGuOFQ3PyEQvF2= M3vKbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KASUMI-1 NWq0XlVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GxV2lEPTB;MUGuOVcyKM7:TR?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
SK-MEL-28 NGLBNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFzLkm3OlQh|ryP MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
RPMI-8226 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF{Lk[yOFEh|ryP MnLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
T47D NVXCd4E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TpcWlEPTB;MUOuNlA6QSEQvF2= NFToVIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HOP-62 M4DK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTwbVB2UUN3ME2xN{41QCEQvF2= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
A2058 M2HzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zFSWlEPTB;MUOuPFE6QSEQvF2= MoDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
SW620 NIPxbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF2LkK0O|Mh|ryP M2TIbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
LCLC-103H MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O0XGlEPTB;MUSuOFg6OiEQvF2= MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HAL-01 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF2LkW3PVYh|ryP NYfES4U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
PANC-08-13 NG\pO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorNTWM2OD1zND65NVA5KM7:TR?= NHfvdXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
COLO-684 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GzcGlEPTB;MUWuN|k4QSEQvF2= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
DEL MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm1W|dKSzVyPUG1MlQ6QSEQvF2= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
K5 NF3TbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;yPZFxUUN3ME2xOk4yPDh4IN88US=> NEW4bGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SK-MEL-24 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\iSG9KSzVyPUG2MlQ3PTJizszN NEnLXII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ACN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC2SnFKSzVyPUG2MlUzQTdizszN MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
H9 NVTYOVFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF4Lk[yOkDPxE1? MmO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
EM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\heldHUUN3ME2xO{4yPDNizszN M{XwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
HSC-4 M{DGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF5Lk[2NFEh|ryP M3XCb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
IGROV-1 NGrJWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjsXWxbUUN3ME2xO{44QDNizszN NX3CdlF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
TE-1 NV;rO4lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknkTWM2OD1zNz65PVY5KM7:TR?= MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
LN-405 NIiwSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfMbFY1UUN3ME2xPU46ODd4IN88US=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
MSTO-211H M1O1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLre4xKSzVyPUKwMlM2PzNizszN MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
MOLT-4 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36yPWlEPTB;MkCuOVc2QSEQvF2= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
RS4-11 NH;BbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv1TWM2OD1{Mj6xOVY{KM7:TR?= NHHJSXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ES3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nJRmlEPTB;MkKuOlk3OyEQvF2= NIn3TXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SBC-1 NFzkd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXlXoJKSzVyPUKzMlg3QTZizszN MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
CTV-1 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELKZ4lKSzVyPUK1MlAyPDlizszN NV3Dem94RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HuP-T3 NHXm[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECzV4hKSzVyPUK1MlQxODlizszN NYDGfIliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCC2218 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDZTWM2OD1{NT61OFA4KM7:TR?= MnzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
HDLM-2 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOxVFA4UUN3ME2yPE4zODJ4IN88US=> Mn3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ABC-1 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;pTWM2OD1{OT62PVc1KM7:TR?= NVL4UmZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MV-4-11 NEnOUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHaTWM2OD1{OT63N|E4KM7:TR?= NVzTOnc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
WM-115 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\JcWlEPTB;M{CuN|A6QSEQvF2= NVjJXmN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
SW1990 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfaVVVMUUN3ME2zNE4{OyEQvF2= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
HCC70 M{POXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe3TWM2OD1|MD63N|Q3KM7:TR?= Ml[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KYSE-520 NGjIUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13tR2lEPTB;M{CuPFg{QSEQvF2= MnTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
JEG-3 NX;6XXYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNzLkG2NVQh|ryP NGHzblQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
C8166 M3TtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzrPYJKSzVyPUOxMlIzPzRizszN NG[2ToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
SK-OV-3 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG4TWM2OD1|MT62O|U2KM7:TR?= MnTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H526 NV7yOY5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXDT2NSUUN3ME2zNk43QDNizszN NELCdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NKM-1 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHGNIJKSzVyPUOyMlk2PjhizszN MnLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ECC10 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G4NGlEPTB;M{SuO|Q1OyEQvF2= NGG3V4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
A2780 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP4N|FLUUN3ME2zOU4{PjBzIN88US=> NFfrdWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
KY821 NGjaWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN3Lke2PFEh|ryP M3mwN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MKN1 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN4LkKxN|ch|ryP M4HTOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
EKVX MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN5LkSyNVIh|ryP MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
EW-16 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDKWmdKSzVyPUO4MlM5QDVizszN M{TqNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
CTB-1 M3;2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDWTWM2OD1|OT63O|g6KM7:TR?= MlThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
COR-L105 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHmTWM2OD12MD60O|Q3KM7:TR?= NYT1SmFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-SNU-5 NE\tRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTRzLkKwOlkh|ryP M1nBb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Mewo NIjRVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1naXmlEPTB;NEGuPVg4OSEQvF2= MofuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
BCPAP MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR|Lke5NVch|ryP M3WyVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KARPAS-45 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zrN2lEPTB;NESuNlc4PiEQvF2= NGrrSnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-H1693 M1zyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7Hd5RIUUN3ME20Ok43QTh4IN88US=> MlrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
H-EMC-SS M33IO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vEN2lEPTB;NEiuN|IzPCEQvF2= MmrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
697 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTVyLkO1OFUh|ryP M3zJWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KP-N-YS NF;0eFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3TZWhKSzVyPUWyMlMyPDJizszN NEHoe5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-H1304 NWnpc|JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLDTWM2OD13Mj63NFI1KM7:TR?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NOS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjL[G1KSzVyPUWyMlg2PTlizszN NHn0dlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-H2342 NWjOUpRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTV|LkC1NFgh|ryP NGP2Sok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
KYSE-270 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInzdoxKSzVyPUWzMlY{PjRizszN MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
LU-135 NGTGRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTV3LkG4OVMh|ryP MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
OE33 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTV3LkixPEDPxE1? NEiyWI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ML-2 M{XsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\5dWlEPTB;NUWuPVQ5QSEQvF2= Ml\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KMOE-2 NF7tNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTV4LkK4PVMh|ryP Mn\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
Daoy MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HpU2lEPTB;NU[uN|IxPCEQvF2= M1;iclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
KNS-62 NV;l[HI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTV5LkCxOFIh|ryP MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NBsusSR NF7uc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTV5LkW3NFUh|ryP NVrofZJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
UACC-257 NGXvN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hj[mlEPTB;NUiuOlI3PCEQvF2= MlXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
LU-139 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLKNIwxUUN3ME21PE45OjZizszN M{S3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
CAL-85-1 NIDicYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTV6Lki2OFMh|ryP NInxSIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-H720 NETvS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjRSnh3UUN3ME21PE45QTR{IN88US=> Ml7kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
MLMA NGTDUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn0TWM2OD13OT6wPVEh|ryP NXPE[4dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
A3-KAW NEPPXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LXemlEPTB;NUmuNlgxQSEQvF2= M2SyZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
Ramos-2G6-4C10 NHPafZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTV7Lk[yPFch|ryP NGTYcos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
A388 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPRWIlQUUN3ME22NE41PDlizszN NVzuXJR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
LAMA-84 M3fVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTZyLkm5NFUh|ryP MkXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
GCT M{j4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLUUmRKSzVyPU[xMlA4QDZizszN MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
K-562 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nib2lEPTB;NkGuOVM{OyEQvF2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
NCI-H1666 NILYPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rhUWlEPTB;NkGuPFc2KM7:TR?= NVKwdmVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H1993 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnVUJo3UUN3ME22N{41ODR|IN88US=> M17BVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
NCI-H358 NFXYfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTZ3LkCxNlEh|ryP NXjuSmxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NB6 NIfSdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZ3Lkm4PEDPxE1? NYi2SXp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCE-T MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDT[VN1UUN3ME22O{4xPzl6IN88US=> MmPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
DOK NYm5U4M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LPWWlEPTB;NkeuOFk1QCEQvF2= NV[wNmNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HT-1376 NYrqeI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIriRVFKSzVyPU[5Mlg{OTRizszN NH7rWWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NEC8 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjQVpBKSzVyPUewMlEzPDNizszN NITrbFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
G-402 NFvIZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdyLkmzPVUh|ryP NFnQZ5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
GR-ST NID1dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P5NmlEPTB;N{GuNVczKM7:TR?= NUXtPGw1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
QIMR-WIL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTdzLkS0N|Qh|ryP NG\z[JU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
CHP-212 NEjYfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXEWWRKSzVyPUexMlk3PSEQvF2= Mm\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
KU812 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTd{Lkm3NFIh|ryP Mo\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
Becker NHX1[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTd|LkG0PFkh|ryP MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
ChaGo-K-1 NFTrbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTd2Lke0PFYh|ryP MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
A498 NVy1T45nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTR2R6UUN3ME23OE46OzB6IN88US=> NVjwWWFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
NCI-H69 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULCW|NLUUN3ME23OU44PjZ|IN88US=> Mln3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
NCI-H209 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrxRnVKSzVyPUe4MlYyPDdizszN MmTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
CAL-33 NU[x[HpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;vUo1{UUN3ME23PE46QTN7IN88US=> M3q4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
COLO-680N NH7xbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\mTWM2OD15OT6xNFA4KM7:TR?= Mln6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
D-283MED NFHhNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;VTWM2OD15OT64NVIh|ryP NEe4dmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
ATN-1 NFnpfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRThzLkGxPFch|ryP NFfL[nE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NCI-N87 NFrRTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTqTWM2OD16MT63Nlk3KM7:TR?= M3rkcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
MHH-NB-11 NUH6[YFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRThzLki4OFkh|ryP NIrJOo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HEL M3rRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTh{LkSxN|Qh|ryP NH\oV4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
NB69 M{S4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO4d4FuUUN3ME24N{4xODN|IN88US=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
MPP-89 NHG4ZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTh|LkK1O|Uh|ryP NFnsR4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
COLO-829 NFPEc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXLNXA3UUN3ME24OU41QTF{IN88US=> NXm3SnRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
ONS-76 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\RTWM2OD16NT63PVA5KM7:TR?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
EW-3 NEPYXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TkVmlEPTB;OE[uNlA{OiEQvF2= NFHTOmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
EW-11 M1O3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TuemlEPTB;OE[uOFM{PiEQvF2= MofEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
SW900 NYrYU29DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TiOGlEPTB;OEeuNlA2OyEQvF2= MkCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
MOLT-13 NGHJfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnnR4dqUUN3ME24O{4zOjR|IN88US=> NEnkWGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
HuP-T4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjnTWM2OD17MT6wOFA2KM7:TR?= NWmwXIR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
HCC1419 NYPSPIlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPVTWM2OD17MT62N|c1KM7:TR?= M2S4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFg1QC9pPmPBUmdGWjxxYU6=
CAL-72 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TiSWlEPTB;OUKuNFIyQSEQvF2= NHn5fGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
Mo-T MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;EcHp7UUN3ME25Nk44Pjl5IN88US=> NYT0RpB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
OC-314 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHwcWxKSzVyPUmyMlg5OjFizszN MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
BHT-101 NYPBTJRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HFSGlEPTB;OUOuNUDPxE1? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4OFgwLz6VQV7HSXI9N2F-
EW-18 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTl|Lki0OlIh|ryP NHjVc|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5PDhxJ{7TRW5ITVJ:L3G+
TE-12 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[3fYxiUUN3ME25OE4{ODV3IN88US=> NXTS[4ZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDR6Lze+V2FPT0WUPD;hQi=>
MDA-MB-361 NELxNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHUS2tKSzVyPUm2MlA2OTZizszN MkXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFQ5Nyd-U1HOS2VTRC:jPh?=
DF15 M2LHN2Z2dmO2aX;uJIF{e2G7 MXy0JIhzew>? M3nrbWlv\HWldHnvckBw\iCFUly0M2NTSk5idXLpdZVqfGmwIHzp[4F{\S2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDlfJBz\XO|aX7nJJBNV0NvZWDMMZRi\2enZDDhbY9td3NiYX\0[ZIhPCCqcoOgZpkhdHWvaX7ld4NmdmOnIHLhd4VlKGKndHGt[4Ft[WO2b4Pp[IF{\SCnbor5cYUh\nKjZ33lcpRifGmxbjDjc41xdGWvZX70ZZRqd25iYYPzZZktKEWFNUCgQUAxNjB3MzFOwG0v NWK3XJZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVg2ODdpPkK4N|U5PTB5PD;hQi=>
DF15 MX3GeY5kfGmxbjDhd5NigQ>? NEXJXms1KGi{cx?= MVHJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDlVGwufGGpZ3XkJIls[XKxczDh[pRmeiB2IHjyd{BjgSCudX3pco9u\XS{aXOgZY5idHm|aYOsJGVEPTBiPTCwMlA3PyEQvF2u NV;vVVJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15 MUfGeY5kfGmxbjDhd5NigQ>? NEiyT4Q1KGi{cx?= NGXrT2lKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BmWExvdHHn[4VlKGGrb3zvd{Bi\nSncjC0JIhzeyCkeTDseY1qdm:vZYTybYMh[W6jbInzbZMtKEWFNUCgQUAxNjB6NzFOwG0v MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
T-cells MYnGeY5kfGmxbjDhd5NigQ>? MUSyJJRwKDNiZHH5dy=> MmPVTY5pcWKrdHnvckBw\iCLTD2yJJBzd2S3Y4Tpc44hcW5iaIXtZY4hXCClZXzsd{Bu\WG|dYLl[EBi\nSncjCyJJRwKDNiZHH5d{BjgSCHTFnTRUwhTUN3MDC9JFAvOTVizszNMi=> NV\DXWxLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlgxOTlpPkKzNVY5ODF7PD;hQi=>
NAMALWA MlziRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NILYc|A4OiCqcoO= NX7HbZZnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDORW1CVFeDIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzOKXYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFczKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD6zOkDPxE1w NHHBVos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G2PFAyQSd-MkOxOlgxOTl:L3G+
CD34+ progenitor cells MVLGeY5kfGmxbjDhd5NigQ>? M{PnWFE1KGSjeYO= Ml\0SIVkemWjc3WgbY4h\XK7dHjyc4llKGSrZn\ldoVvfGmjdHnvckBw\iCFREO0L{Bxem:pZX7peI9zKGOnbHzzJIZzd21ibYnlcI9lgXOybHHzeIlkKHO7bnTyc41mKGSnbDi1dUkheGG2aXXueEBie3Onc4Pl[EBieyCFREO2JIV5eHKnc4Ppc44h[W[2ZYKgNVQh\GG7cx?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5NkmyOEc,OTd3N{[5NlQ9N2F-
CD34+ progenitor cells M1LydmZ2dmO2aX;uJIF{e2G7 MXixOEBl[Xm| M{nTPWRm[3KnYYPlJIlvKG27ZXzvbYQh\GmoZnXy[Y51cWG2aX;uJI9nKEOGM{SrJJBzd2enbnn0c5Ih[2WubIOg[pJwdSCveXXsc4R6e3CuYYP0bYMhe3mwZILvcYUh\GWuKEXxLUBx[XSrZX70JIF{e2W|c3XkJIF{KEOGM{Og[ZhxemW|c3nvckBi\nSncjCxOEBl[Xm| MkK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[5NlQoRjF5NUe2PVI1RC:jPh?=
CD34+ progenitor cells MW\GeY5kfGmxbjDhd5NigQ>? MVSxOEBl[Xm| NY\MRXVOTGWlcnXhd4UhcW5iZYL5eIhzd2mmIHTp[oZmemWwdHnheIlwdiCxZjDDSFM1MyCycn;n[Y5qfG:{IHPlcIx{KG[{b32gcZlmdG:meYPwcIF{fGmlIIP5coRzd22nIHTlcEg2eSlicHH0bYVvfCCjc4Pld5Nm\CCjczDncJlkd3Cqb4LpckBCKGW6cILld5Nqd25iYX\0[ZIhOTRiZHH5dy=> MkTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3N{[5NlQoRjF5NUe2PVI1RC:jPh?=
CD34+ progenitor cells M{H1O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfscFYyPCCmYYnz M1LINWlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;mJGNFOzRtIIDyc4dmdmm2b4KgZ4VtdHNiZoLvcUBugWWub3T5d5Bt[XO2aXOgd5lv\HKxbXWg[IVtMDWzKTDwZZRq\W62IHHmeIVzKDF2IHThfZM> NHriSVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W3OlkzPCd-MUe1O|Y6OjR:L3G+
CD34+ progenitor cells NHXJVHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHLHOHEyPCCmYYnz NFWwcVlIem:5dHigbY5pcWKrdHnvckBw\iCFREO0L{Bxem:pZX7peI9zKGOnbHzzJIZzd21ibn;uMYRmdCh3cTmgcZlmdG:meYPwcIF{fGmlIIP5coRzd22nIIDheIlmdnRiYX\0[ZIhOTRiZHH5dy=> NILjNZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W3OlkzPCd-MUe1O|Y6OjR:L3G+
DF15 MWDGeY5kfGmxbjDhd5NigQ>? M4Hj[lAvOSC2bzCxNEB2VQ>? MoLUOUBpenN? NHnHSWhKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5zIITvJFExKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NVLiUVZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 NXXFWFMxTnWwY4Tpc44h[XO|YYm= M335[VAvOSC2bzCxNEB2VQ>? MYm1JIhzew>? M3;TNmlv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iT2DNNkBk\WyuczDheEAxNjFidH:gNVAhfU1iYX\0[ZIhPSCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NG\Geo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
DF15 M1qx[mZ2dmO2aX;uJIF{e2G7 NFn1V2QxNjFidH:gNVAhfU1? NFfSfnQ2KGi{cx?= Mlv0TY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHH0JFAvOSC2bzCxNEB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
OPM2 M1HvNmZ2dmO2aX;uJIF{e2G7 NGSyS5gxNjFidH:gNVAhfU1? NYTF[JFSPSCqcoO= NXPvfmNnUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHnrZZJweyCmZXfyZYRifGmxbjDpckBpfW2jbjDPVG0zKGOnbHzzJIF1KDBwMTD0c{AyOCC3TTDh[pRmeiB3IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
EC9706 MlvURY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NUTqSlBLOTVyIIXnM41N MVi0PEBpenN? NWDTO5d4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFR|k4ODZiY3XscJMh[XRiMUWwJJVoN22OIHHmeIVzKDR6IHjyd{BjgSCFQ1utPEBie3OjeR?= M2f1WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W3NFY3Lz5{OEe1O|A3PjxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-IKKβ / IKKβ ; 

PubMed: 22698399     


Western blot analysis of the indicated proteins following treatment of OCI-Ly10 cells with lenalidomide (10μM) for the indicated times. 

MDM2 / p-MDM2 / p-p53 / p53 ; 

PubMed: 22525275     


(a) Treatment with lenalidomide (Len) increases phosphorylation of ser46 and thr55 of p53. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were prepared and analyzed by Western blotting with antibodies to MDM2, phospho-ser46 of p53, phospho-thr55 of p53 and total p53. (b) Treatment with lenalidomide increases phosphorylation of MDM2 at ser166 and ser186. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were immunoprecipitated using anti-MDM2 antibody. The samples were separated by SDS PAGE and then Western blotted with either anti-MDM2 or antibodies specific to phospho-ser166, phospho-ser186, total phospho-serine or total phospho-threonine of MDM2 as indicated. 

22698399 22525275
Growth inhibition assay
Cell viability; 

PubMed: 22698399     


Viability (MTS assay) of ABC and GCB DLBCL cell lines treated with lenalidomide for 4 days. Error bars show the standard error of the mean (SEM) of triplicates.

22698399
In vivo The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

Protocol

Animal Research:

[5]

- Collapse
  • Animal Models: Adult male Sprague-Dawley rats bearing HUVECs cells
  • Dosages: 50 mg/kg and 250 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG 300+5%Tween80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.26
Formula

C13H13N3O3

CAS No. 191732-72-6
Storage powder
in solvent
Synonyms N/A
Smiles C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04903197 Not yet recruiting Drug: VAY736|Drug: lenalidomide Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Novartis Pharmaceuticals|Novartis September 30 2021 Phase 1
NCT04974216 Not yet recruiting Drug: Tafasitamab|Drug: Lenalidomide|Drug: Rituximab DLBCL The Lymphoma Academic Research Organisation September 15 2021 Phase 2
NCT04669171 Recruiting Biological: EO2463|Drug: lenalidomide|Biological: rituximab Follicular Lymphoma|Marginal Zone Lymphoma Enterome July 5 2021 Phase 1|Phase 2
NCT04796857 Recruiting Drug: PD-1 Antibody|Drug: Lenalidomide Non-GCB/ABC Diffuse Large B-Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL Nos|ALK-Positive Anaplastic Large Cell Lymphoma Huiqiang Huang|Sun Yat-sen University March 31 2021 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the formulation for mouse injection(i.p.)?

  • Answer:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • Question 2:

    what is the procedure to resuspend this compound?

  • Answer:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

E3 ligase Ligand Inhibitors with Unique Features

Tags: buy Lenalidomide (CC-5013) | Lenalidomide (CC-5013) supplier | purchase Lenalidomide (CC-5013) | Lenalidomide (CC-5013) cost | Lenalidomide (CC-5013) manufacturer | order Lenalidomide (CC-5013) | Lenalidomide (CC-5013) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID